Evidence map›Paper›PMID 38987188›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Durable Response of Pembrolizumab for EGFR Mutation-positive Lung Adenocarcinoma with Early Progression to Osimertinib in First-line Treatment.

Aoi Miyazaki, Koichi Saruwatari, Toru Yamanaka, Kenji Shiraishi, Yusuke Tomita, Hidenori Ichiyasu, Takuro Sakagami

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Aoi MiyazakiDepartment of Respiratory Medicine, National Hospital Organization Kumamoto Minami Hospital, Japan.
Koichi SaruwatariDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan.
Toru YamanakaDepartment of Respiratory Medicine, National Hospital Organization Kumamoto Minami Hospital, Japan.
Kenji ShiraishiDepartment of Surgery, National Hospital Organization Kumamoto Minami Hospital, Japan.
Yusuke TomitaDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan.
Hidenori IchiyasuDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan.
Takuro SakagamiDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kumamoto University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor, is the standard first-line treatment for EGFR mutation-positive non-small-cell lung cancer (NSCLC) and demonstrates favorable disease control. Conversely, immune checkpoint inhibitors (ICIs) that target programmed cell death-1/programmed cell death ligands demonstrate a restrictive tumor response. We herein report a patient who achieved a durable response to pembrolizumab following early progression within two months of osimertinib administration for EGFR mutation-positive lung adenocarcinoma. Our findings suggest that treatment with ICIs for patients with EGFR mutation-positive NSCLC experiencing early progression to osimertinib as first-line treatment might represent a viable approach.

Indexed as

AcrylamidesAdenocarcinoma of LungAniline CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalLung NeoplasmsDisease ProgressionErbB ReceptorsHumansIndolesMutationPyrimidinesTreatment OutcomeAcrylamidesAniline CompoundsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalEGFR protein, humanErbB ReceptorsIndolesosimertinibpembrolizumabPyrimidinesanti-programmed cell death-1EGFR mutationnon-small-cell lung cancerosimertinibprogrammed cell death-ligand antibody

Identifiers

PMID38987188
PMCPMC11904448

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.